Compare Immunovant Inc. Common Stock (IMVT) vs Taskus Inc (TASK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs Taskus Inc — how do they compare? Immunovant Inc. Common Stock trades at $30.13 (market cap $6.25B), while Taskus Inc trades at $8.15 (market cap $723.41M). The key difference: Immunovant Inc. Common Stock is far larger — about 8.6× Taskus Inc's market cap, and Immunovant Inc. Common Stock is trading nearer its 52-week high, Taskus Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 0 Days and Taskus Inc for 34 Days on average.
| IMVT | TASK | |
|---|---|---|
Market Cap | $6.25B | $723.41M |
Volume | 1,755,411 | 201,303 |
Sector | Health | Technology |
52-Week High | $44.96 | $14.69 |
52-Week Low | $17.03 | $4.57 |
Typical Hold Time | 0 Days | 34 Days |
Enterprise Value | $5.35B | $1.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TaskUs (TASK) trades at $8.06, up 2.15% today, with a bearish technical signal but strong fundamentals. Revenue reached $1.18 billion in 2025, with net income surging to $102.28 million and an 8.75% margin. The stock appears undervalued with a P/E of 6.8 and P/S of 0.6. Recent news highlights AI-driven growth offsetting legacy declines, with Q2 2026 earnings beating estimates.
The outlook is mixed: low valuation and AI expansion offer upside, but technical weakness and margin pressure from labor costs pose risks. Analysts are generally bullish with a $9.33 consensus target, implying 16% upside, though competitive and execution challenges remain key watchpoints for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About Taskus Inc
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to innovative and disruptive technology companies. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
Read more on TASK →
